MIME-Version: 1.0
Server: WebSTAR/2.1 ID/32304
Message-ID: <b0b80f5a.3987@www.epixmed.com>
Date: Sun, 14 Dec 1997 19:50:14 GMT
Last-Modified: Tue, 01 Jul 1997 00:14:56 GMT
Content-type: text/html
Content-length: 3406

<HTML><HEAD>   <TITLE>Epix Medical Home Page</TITLE></HEAD><BODY BGCOLOR="#FFFFFF"><H1><CENTER><IMG SRC="graphics/logo_spacer.gif" WIDTH=113 HEIGHT=50ALIGN=bottom><IMG SRC="graphics/about_banr.gif" WIDTH=320 HEIGHT=50ALIGN=bottom><BR><A HREF="index.html"><IMG SRC="graphics/hometabs.gif" ALT="Home"WIDTH=67 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="index2.html"><IMGSRC="graphics/aboutabs.gif" ALT="About EPIX" WIDTH=99 HEIGHT=21BORDER=0 ALIGN=bottom></A><A HREF="ms325.html"><IMGSRC="graphics/m325tabs.gif" ALT="MS-325" WIDTH=76 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="technology.html"><IMGSRC="graphics/techtabs.gif" ALT="Technology R&amp;D" WIDTH=137HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="http://www.prnewswire.com/prn/owa/cn_liststory?id=120427"><IMGSRC="graphics/newstabs.gif" ALT="News" WIDTH=54 HEIGHT=21 BORDER=0ALIGN=bottom></A><BR><A HREF="publications.html"><IMG SRC="graphics/paprtabs.gif"ALT="Publications" WIDTH=109 HEIGHT=21 BORDER=0ALIGN=bottom></A><A HREF="employment.html"><IMGSRC="graphics/jobstabs.gif" ALT="Employment Opportunities" WIDTH=107HEIGHT=21 BORDER=0 ALIGN=bottom></A><A HREF="investor.html"><IMGSRC="graphics/invetabs.gif" ALT="Investor Info" WIDTH=106 HEIGHT=21BORDER=0 ALIGN=bottom></A><A HREF="request.html"><IMGSRC="graphics/datatabs.gif" ALT="Request Information" WIDTH=111HEIGHT=21 BORDER=0 ALIGN=bottom></A></CENTER></H1><H1><HR>Company Overview</H1><P>Based in Cambridge, Mass., EPIX Medical, Inc. (Nasdaq: EPIX) isdeveloping targeted contrast agents to improve the capability andexpand the use of magnetic resonance imaging (MRI) as a tool fordiagnosing human disease. The lead product under development, MS-325,is an injectable contrast agent designed for multiple vascularimaging indications, including coronary artery disease and peripheralvascular disease.<P>EPIX believes that MS-325 will significantly enhance image qualityand provide physicians with a clinically superior, noninvasive andcost-effective method for diagnosing cardiovascular disease. MS-325should also simplify the diagnosis for many diseases and in manycases replace highly invasive and expensive X-ray angiography --currently considered the definitive diagnostic exam forcardiovascular disease.<P>An estimated 3.5 million X-ray angiograms are performed in theUnited States each year at an estimated cost to the health caresystem of over $6 billion. A growing worldwide problem,cardiovascular disease kills approximately one million people in theUnited States each year, making it the nation's leading cause ofdeath.<P><TABLE BORDER=0>   <TR>      <TD COLSPAN=2>         <P><CENTER><IMG SRC="images/ALBUMIN.gif" WIDTH=364         HEIGHT=258 ALIGN=bottom></CENTER>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><CENTER><B>Illustration showing MS-325 being injected         into the blood stream and attaching to the protein albumin.         MS-325 is designed to provide enhanced signals to an MRI         scanner, thereby improving the quality of the images of the         vasculature.</B></CENTER>      </TD></TR></TABLE><P><CENTER><HR>&copy; 1997, EPIX Medical, Inc.<BR><P><CENTER>E-mail us at<A HREF="mailto:info@epixmed.com">info@epixmed.com</A></CENTER><P><CENTER>&nbsp;</CENTER></BODY></HTML>